Several phase III trials using lenvatinib in NSCLC are being examined the efficacy of pembrolizumab in combination with pemetrexed plus platinum in the first-line treatment of non-squamous NSCLC patients (LEAP-006, NCT03829319), in combination with pembrolizumab in the first-line treatment of PD-L1-positive patients (LEAP-007, NCT03829332), in combination with docetaxel in the second-line setting (LEAP-008, NCT03976375), and in combination with KN046, a recombinant humanized PD-L1/CTLA-4 bispecific fusion protein, after ICI resistance (NCT05001724). Here, CD274 is linked to non-small cell lung carcinoma.